BusinessRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority ReviewBy Nasdaq OMXMar 21, 2016, 8:05 PM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate UpdateBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
BusinessRaptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ETBy Nasdaq OMXFeb 18, 2016, 12:30 PM UTC
